{"id":"W2331564155","doi":"10.1097/01.mib.0000480206.37277.e8","title":"P-101 Incidence of Anti-drug Antibodies in Crohnʼs Disease Patients During 5 Years of Certolizumab Pegol Therapy","year":2016,"lang":"en","type":"article","venue":"Inflammatory Bowel Diseases","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":5,"is_retracted":false,"has_abstract":true,"ca_institutions":"Robarts Clinical Trials","funders":"","keywords":"Certolizumab pegol; Medicine; Dosing; Internal medicine; Placebo; Antibody; Vedolizumab; Gastroenterology; Maintenance therapy; Concomitant; Incidence (geometry); Disease; Crohn's disease; Immunology; Infliximab; Chemotherapy; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006397131,0.0002105823,0.0005112903,0.000877113,0.0003588957,0.0009417555,0.0003100838,0.0007938845,0.001918309],"category_scores_gemma":[0.002747474,0.0002221478,0.000630802,0.001019221,0.0002559752,0.0009866054,0.0004431483,0.0009080829,0.0004062329],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004429519,"about_ca_system_score_gemma":0.0003230353,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001635794,"about_ca_topic_score_gemma":0.001248105,"domain_scores_codex":[0.9992005,0.0001791499,0.00009066814,0.0001449683,0.0002242387,0.0001603842],"domain_scores_gemma":[0.9974902,0.0003845256,0.001330135,0.00007388142,0.0002173725,0.0005039863],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0008733131,0.00008677363,0.9934028,0.00002108157,0.00007201941,0.0005988936,0.00005532594,0.00005537065,0.0002950282,0.00002850971,0.0002016935,0.004309249],"study_design_scores_gemma":[0.00005116816,0.0007636768,0.9967086,0.00001390191,0.00004942754,0.001511207,0.0001051265,0.0002657377,0.00007454152,0.0000340949,0.0004152853,0.00000719695],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9970006,0.0008922849,0.00008629209,0.00008504317,0.00001995283,0.00001675447,0.0003303743,0.000007006507,0.001561633],"genre_scores_gemma":[0.9992181,0.0001604133,0.00002750044,0.00004890925,0.00002251941,0.000006979335,0.0003258479,0.000001227788,0.0001885041],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001918309,"threshold_uncertainty_score":0.006417394,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.005420288196716291,"score_gpt":0.2248588143653579,"score_spread":0.2194385261686416,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}